Is AVTX or AVXL more undervalued in 2026?

CirclFi compares Avalo Therapeutics, Inc. (AVTX) and Anavex Life Sciences Corp. (AVXL) using 13 institutional-grade valuation models. AVTX has a Quality of Company score of 4.7/10 while AVXL scores 4.3/10.

Which is a better buy — AVTX or AVXL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AVTX and AVXL valuations compare?

AVTX at $16.13 and AVXL at $2.94 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AVTX vs AVXL Valuation Comparison 2026 — Intrinsic Value Analysis

AVTX

Biotechnology

Avalo Therapeutics, Inc.

Quality

4.7

out of 10

Value Trap

WARN

Price

$16.13

Last close

Models

9/13

Active

AVXL

Biotechnology

Anavex Life Sciences Corp.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$2.94

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	AVTX Fair Value	AVTX Upside	AVXL Fair Value	AVXL Upside
Bayesian DCF	Intrinsic	$4.59	-71.6%	$1.56	-46.8%
Earnings Power Value	Intrinsic	—	—	$1.52	-54.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.69	-95.7%	$0.37	-88.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AVTX vs AVXL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AVTX vs AVXL — Which Stock Is More Undervalued?

AVTX scores higher with a 4.7/10 quality rating vs AVXL's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Avalo Therapeutics, Inc. (AVTX) and Anavex Life Sciences Corp. (AVXL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AVTX currently trades at $16.13 with a QOC of 4.7/10, while AVXL trades at $2.94 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).